Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific, Cook to develop paclitaxel-coated stents under deal with Angiotech.

This article was originally published in The Gray Sheet

Executive Summary

BOSTON SCIENTIFIC, COOK TO EVALUATE PACLITAXEL-COATED STENTS under a three-way development pact with pharmaceutical firm Angiotech. According to terms of the deal, announced July 10, Boston Scientific and Cook each will take a 2% stake in Vancouver-based Angiotech and will make subsequent milestone payments that could make the deal worth as much as 32 mil. Canadian dollars ($23.3 mil. USD). Under the agreement, Angiotech licenses to BSC and Cook the use of paclitaxel, an anti-cancer drug, and related compounds as a coating for stents "and other endoluminal devices" used to treat vascular and gastrointestinal diseases, Angiotech says.

You may also be interested in...



Boston Scientific v. Cook

Ruling on summary judgement motions is slated for June 6 in the firms' dispute over the license of paclitaxel-coating technology from Cook to Guidant for its Achieve drug-coated stent, according to Boston Scientific. No trial would be required for issues decided on summary judgement by the Northern Illinois federal court. Boston Scientific alleges that the licensing agreement violates a co-exclusive agreement for the technology reached with Canadian firm Angiotech Pharmaceuticals and Cook in 1997 (1"The Gray Sheet" July 14, 1997, I&W-1). The court has dismissed a Cook claim of unfair trade practices but declined to dismiss Cook's anti-trust claim, according to Boston Scientific. Guidant maintains that its agreement with Cook establishes a legal distributor relationship with the privately held firm...

Boston Scientific v. Cook

Ruling on summary judgement motions is slated for June 6 in the firms' dispute over the license of paclitaxel-coating technology from Cook to Guidant for its Achieve drug-coated stent, according to Boston Scientific. No trial would be required for issues decided on summary judgement by the Northern Illinois federal court. Boston Scientific alleges that the licensing agreement violates a co-exclusive agreement for the technology reached with Canadian firm Angiotech Pharmaceuticals and Cook in 1997 (1"The Gray Sheet" July 14, 1997, I&W-1). The court has dismissed a Cook claim of unfair trade practices but declined to dismiss Cook's anti-trust claim, according to Boston Scientific. Guidant maintains that its agreement with Cook establishes a legal distributor relationship with the privately held firm...

Boston Scientific Disputes Cook Collaboration With Guidant On Coated Stents

Favorable six-month results from a Cook 21-patient, paclitaxel-coated coronary stent pilot study, including zero restenosis, appear to bode well for the larger ELUTES European study. Six-month ELUTES data are slated to be released at the American Heart Association meeting in November.

Related Content

UsernamePublicRestriction

Register

MT008388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel